Roivant Sciences LTD. (ROIV) — SEC Filings

Overview

Roivant Sciences LTD. (ROIV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 21, 2026: On April 17, 2026, James C. Momtazee reported a change in beneficial ownership of securities for Roivant Sciences Ltd. The filing details transactions related to his holdings, but specific dollar amounts and the exact nature of the transactions are not provided in this excerpt.

Sentiment Summary

Across 47 filings, the sentiment breakdown is: 1 bearish, 44 neutral, 2 mixed. The dominant filing sentiment for Roivant Sciences LTD. is neutral.

Filing Type Overview

Roivant Sciences LTD. (ROIV) has filed 2 4, 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 12 SC 13G/A, 3 SC 13G with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (47)

• Roivant Sciences Ltd. Insider Trading Update — 4 · Apr 21, 2026 Risk: medium
  On April 17, 2026, James C. Momtazee reported a change in beneficial ownership of securities for Roivant Sciences Ltd. The filing details transactions related t
• Roivant Sciences Files 8-K: Operations & Financial Update — 8-K · Apr 2, 2026 Risk: low
  Roivant Sciences Ltd. filed an 8-K on April 2, 2026, reporting on their Results of Operations and Financial Condition, and providing Regulation FD Disclosures.
• Roivant Sciences Ltd. Files Form 4 — 4 · Mar 31, 2026 Risk: low
  On March 26, 2026, Roivant Sciences Ltd. (CIK: 0001635088) filed a Form 4, indicating a change in beneficial ownership of securities. The filing was accepted by
• Roivant Sciences Ltd. Files 8-K — 8-K · Dec 11, 2025 Risk: low
  Roivant Sciences Ltd. filed an 8-K on December 11, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing
• 8-K Filing — 8-K · Nov 10, 2025
• Roivant's Revenue Plummets 65% Amidst Deepening Losses — 10-Q · Nov 10, 2025 Risk: high
  Roivant Sciences Ltd. reported a significant decrease in revenue for the three months ended September 30, 2025, falling to $1.571 million from $4.475 million in
• Roivant Sciences Files 8-K — 8-K · Sep 17, 2025 Risk: low
  Roivant Sciences Ltd. filed an 8-K on September 17, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and E
• Roivant Sciences Files 8-K on Shareholder Votes & Financials — 8-K · Sep 11, 2025 Risk: low
  Roivant Sciences Ltd. filed an 8-K on September 11, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing deta
• Roivant Sciences Ltd. Files 8-K — 8-K · Sep 3, 2025 Risk: low
  Roivant Sciences Ltd. filed an 8-K on September 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, othe
• Roivant Narrows Q1 Loss to $150.5M on Cost Cuts, Revenue Growth — 10-Q · Aug 11, 2025 Risk: medium
  Roivant Sciences Ltd. (ROIV) reported a net loss of $150.5 million for the quarter ended June 30, 2025, a significant improvement from the $250.0 million net lo
• Roivant Sets 2025 AGM for Director Elections, Auditor Ratification — DEF 14A · Jul 29, 2025 Risk: low
  Roivant Sciences Ltd. (ROIV) has filed a DEF 14A for its Annual General Meeting of Shareholders on September 10, 2025, at the Royal Lancaster London Hotel. The
• Roivant Sciences Files 8-K: Other Events & Exhibits — 8-K · Jun 25, 2025 Risk: low
  Roivant Sciences Ltd. filed an 8-K on June 25, 2025, reporting "Other Events" and "Financial Statements and Exhibits" as of June 24, 2025. The filing does not d
• 10-K Filing — 10-K · May 29, 2025
• Roivant Sciences Files 8-K — 8-K · Apr 21, 2025 Risk: low
  Roivant Sciences Ltd. filed an 8-K on April 21, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing provides no specifi
• Roivant Sciences Ltd. Files 8-K on Officer/Director Changes — 8-K · Mar 20, 2025 Risk: medium
  Roivant Sciences Ltd. filed an 8-K on March 20, 2025, reporting events as of March 16, 2025. The filing pertains to the departure of directors or certain office
• Roivant Sciences Files 8-K — 8-K · Mar 19, 2025 Risk: low
  Roivant Sciences Ltd. filed an 8-K on March 19, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Ev
• Roivant Sciences Ltd. Reports Board and Executive Compensation Changes — 8-K · Feb 21, 2025 Risk: medium
  Roivant Sciences Ltd. announced on February 19, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departur
• Roivant Sciences Files Q3 2024 10-Q — 10-Q · Feb 10, 2025 Risk: medium
  Roivant Sciences Ltd. filed its 10-Q for the period ending December 31, 2024. The company reported financial results for the third quarter and the first nine mo
• Roivant Sciences Files 8-K: Financial Statements & Exhibits — 8-K · Dec 3, 2024 Risk: low
  On December 3, 2024, Roivant Sciences Ltd. filed an 8-K report. The filing primarily serves as a notification of financial statements and exhibits, as well as a
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Roivant Sciences Files Q2 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Roivant Sciences Ltd. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the second quarter and the first half
• SC 13G Filing — SC 13G · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• Roivant Sciences Terminates Material Definitive Agreement — 8-K · Oct 28, 2024 Risk: medium
  Roivant Sciences Ltd. announced on October 28, 2024, the termination of a material definitive agreement. The company also filed a Regulation FD Disclosure and F
• SC 13G Filing — SC 13G · Oct 24, 2024
• Roivant Sciences Enters Material Definitive Agreement — 8-K · Sep 23, 2024 Risk: medium
  Roivant Sciences Ltd. announced on September 17, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of th
• Roivant Sciences Ltd. Files 8-K — 8-K · Sep 18, 2024 Risk: low
  Roivant Sciences Ltd. filed an 8-K on September 18, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific
• Roivant Sciences Ltd. Files 8-K with Shareholder Vote and Financials — 8-K · Sep 16, 2024 Risk: low
  Roivant Sciences Ltd. filed an 8-K on September 16, 2024, reporting on matters submitted to a vote of security holders and including financial statements and ex
• Roivant Sciences Files 8-K — 8-K · Sep 10, 2024 Risk: low
  Roivant Sciences Ltd. filed an 8-K on September 10, 2024, to report information under Regulation FD Disclosure and Financial Statements and Exhibits. The filing
• Roivant Sciences Files 8-K — 8-K · Sep 9, 2024 Risk: low
  Roivant Sciences Ltd. filed an 8-K on September 9, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific f
• Roivant Sciences Q1 Revenue Surges, R&D Costs Climb — 10-Q · Aug 9, 2024 Risk: medium
  Roivant Sciences Ltd. filed its 10-Q for the period ending June 30, 2024. The company reported License, Milestone, and Other Revenue of $100.5 million for the f
• Roivant Sciences Ltd. Files 8-K — 8-K · Aug 8, 2024 Risk: low
  Roivant Sciences Ltd. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing does not contain specific finan
• Roivant Sciences Files Definitive Proxy Statement — DEF 14A · Jul 26, 2024 Risk: low
  Roivant Sciences Ltd. filed its definitive proxy statement (DEF 14A) on July 26, 2024, for its annual meeting on September 10, 2024. The filing outlines the com
• Roivant Sciences Files 2024 10-K — 10-K · May 30, 2024 Risk: medium
  Roivant Sciences Ltd. filed its 2024 10-K report, detailing its fiscal year ending March 31, 2024. The company, operating in pharmaceutical preparations, is hea
• SC 13G/A Filing — SC 13G/A · Apr 2, 2024
• Roivant Sciences Files 8-K for Other Events — 8-K · Apr 2, 2024 Risk: low
  Roivant Sciences Ltd. filed an 8-K on April 2, 2024, to report other events and financial statements. The filing does not contain specific details about new eve
• SC 13G/A Filing — SC 13G/A · Mar 7, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Roivant Sciences Ltd. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 13, 2024 Risk:
  Roivant Sciences Ltd. (ROIV) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. Roivant Sciences Ltd. filed its 10-Q report for the period endin
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Sumitomo Chemical Holds 9.0% Stake in Roivant Sciences — SC 13G/A · Feb 1, 2024
  Sumitomo Chemical Co., Ltd. filed an amended SC 13G/A on February 1, 2024, disclosing its beneficial ownership in Roivant Sciences Ltd. As of December 31, 2023,

Related Companies

IMVT

Frequently Asked Questions